Metabolic brain diseaseSep 9, 2026

Postbiotics as a new treatment approach for Parkinson's disease: Understanding molecular actions and brain protection

Gut-Brain Axis Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 10, 2026

Abstract

Postbiotics may represent a promising therapeutic strategy for targeting neurodegenerative processes in Parkinson's disease (PD).

Parkinson's disease is associated with dopaminergic neuronal impairment, mitochondrial dysfunction, and chronic neuroinflammation.
Gut dysbiosis can lead to increased intestinal permeability and systemic inflammation, which may worsen motor and non-motor symptoms of PD.
Bioactive metabolites produced by beneficial microorganisms, known as postbiotics, have the potential to regulate neuroinflammation and improve gut and blood-brain barrier integrity.
Preclinical evidence suggests that postbiotics, particularly butyrate, may alleviate oxidative stress and inhibit the aggregation of misfolded proteins associated with PD.
Emerging clinical evidence indicates that enhancing endogenous postbiotic synthesis could improve gastrointestinal symptoms and reduce inflammatory biomarkers in PD patients.
Further research is needed to assess the safety, efficacy, and optimal dosing of postbiotic interventions in the context of PD.

Simplified

Parkinson's disease (PD) is an aging neurodegenerative disease associated with dopaminergic neuronal impairment, mitochondrial dysfunction, oxidative stress, chronic neuroinflammation, and pathological deposits of misfolded α-synuclein. Gut microbiota (GM) is a general contributing factor in PD pathogenesis via the microbiota-gut-brain bidirectional axis. Gut dysbiosis facilitates intestinal permeability, systemic inflammation, disrupted metabolism of neurotransmitters and amplified α-synuclein aggregation, deteriorates motor and non-motor symptoms. These bioactive metabolites and structural components that beneficial microorganisms generate, known as postbiotics, have been highlighted as having the capacity to regulate neuroinflammation, mitochondrial functionality, synaptic signaling, gut and blood-brain barrier integrity. Short-chain fatty acids (SCFAs), bioactive peptides, bacterial lysates, and exopolysaccharides are compounds with potent neuroprotective and anti-inflammatory properties that are applicable to PD. Preclinical evidence shows that postbiotics, especially butyrate, have the ability to alleviate oxidative stress, inhibit microglial activation, prevent α-synuclein aggregation, and improve behavioral performance in PD models. The emerging clinical evidence also indicates that the optimization of endogenous postbiotic synthesis positively influences gastrointestinal (GI) symptoms and decreases inflammatory biomarkers, and changes GM in PD patients. This review summarizes the mechanistic activities of postbiotics on pathways involved in the pathogenesis of PD and synthesizes recent findings of the therapeutic usefulness of postbiotics. Overall, postbiotics may represent a promising therapeutic strategy for targeting neurodegenerative processes in PD, although their safety, efficacy, optimal dosing, and clinical utility require further investigations. Further studies of specific postbiotic interventions and strategies targeting the microbiota-gut-brain axis are needed to determine their potential to improve the quality of life of patients with PD.

Full Text

Full text is available at the source.

View Full Text ↗

Postbiotics as a new treatment approach for Parkinson's disease: Understanding molecular actions and brain protection

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the gut-brain axis brief